With the preparation of the Joint Action 3 on HTA switching into high gear, confirmation of the immediate practical relevance of the HTA activities are coming in - both from the national and larger European level events of the recent days.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is expecting as many as 5000 participants in its 18th Annual European Congress in Milan, Italy.
The first formal meeting in preparation of the Joint Action 3 on HTA (as put forward in the 2015 Work Programme of the EU Health Programme) took place on October 15, 2015 in Brussels
We are pleased to announce that as of today, 21 October, 2015, the methodological guideline “Endpoints used in Relative Effectiveness Assessment - Safety”, originally published in March 2013 and now adapted within WP7 - Subgroup 3, has entered the public consultation phase.
We are pleased to announce that as of today, 15 October, the Second Draft Report focusing on the production of a Rapid Relative Effectiveness Assessment of new pharmaceuticals for the treatment of chronic hepatitis C by Work Package 5, Strand A has entered the public consultation phase.